Roncador, G.; Puñet-Ortiz, J.; Maestre, L.; Rodríguez-Lobato, L.G.; Jiménez, S.; Reyes-García, A.I.; García-González, Á.; García, J.F.; Piris, M.Á.; Montes-Moreno, S.;
et al. CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers 2022, 14, 2154.
https://doi.org/10.3390/cancers14092154
AMA Style
Roncador G, Puñet-Ortiz J, Maestre L, Rodríguez-Lobato LG, Jiménez S, Reyes-García AI, García-González Á, García JF, Piris MÁ, Montes-Moreno S,
et al. CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers. 2022; 14(9):2154.
https://doi.org/10.3390/cancers14092154
Chicago/Turabian Style
Roncador, Giovanna, Joan Puñet-Ortiz, Lorena Maestre, Luis Gerardo Rodríguez-Lobato, Scherezade Jiménez, Ana Isabel Reyes-García, Álvaro García-González, Juan F. García, Miguel Ángel Piris, Santiago Montes-Moreno,
and et al. 2022. "CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma" Cancers 14, no. 9: 2154.
https://doi.org/10.3390/cancers14092154
APA Style
Roncador, G., Puñet-Ortiz, J., Maestre, L., Rodríguez-Lobato, L. G., Jiménez, S., Reyes-García, A. I., García-González, Á., García, J. F., Piris, M. Á., Montes-Moreno, S., Rodríguez-Justo, M., Mena, M.-P., Fernández de Larrea, C., & Engel, P.
(2022). CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers, 14(9), 2154.
https://doi.org/10.3390/cancers14092154